Based on these data, and knowing that even cells with low SSTRs expression can exhibit a significant SSAs-response [67], we next explored the direct effects of different SSAs (first/second-generation), and selective SSTR1/SSTR2/SSTR5-agonists on the proliferation-rate of patient-derived primary GBM cell-cultures. The gene discussed is SSTR5; the disease is glioblastoma.